MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ajt.12083

Медицинская библиотека · American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2013

Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.

Chung R T, Gordon F D, Curry M P, Schiano T D, Emre S, Corey K, Markmann J F, Hertl M, Pomposelli J J, Pomfret E A, Florman S, Schilsky M, Broering T J, Finberg R W, Szabo G, Zamore P D, Khettry U, Babcock G J, Ambrosino D M, Leav B, Leney M, Smith H L, Molrine D C

СтатьяРандомизированное исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Rapid allograft infection complicates liver transplantation (LT) in patients with hepatitis C virus (HCV). Pegylated interferon-α and ribavirin therapy after LT has significant toxicity and limited efficacy. The effect of a human monoclonal antibody targeting the HCV E2 glycoprotein (MBL-HCV1) on viral clearance was examined in a randomized, double-blind, placebo-controlled pilot study in patients infected with HCV genotype 1a undergoing LT. Subjects received 11 infusions of 50 mg/kg MBL-HCV1 (n=6) or placebo (n=5) intravenously with three infusions on day of transplant, a single infusion on days 1 through 7 and one infusion on day 14 after LT. MBL-HCV1 was well-tolerated and reduced viral load for a period ranging from 7 to 28 days. Median change in viral load (log10 IU/mL) from baseline was significantly greater (p=0.02) for the antibody-treated group (range -3.07 to -3.34) compared to placebo group (range -0.331 to -1.01) on days 3 through 6 posttransplant. MBL-HCV1 treatment significantly delayed median time to viral rebound compared to placebo treatment (18.7 days vs. 2.4 days, p<0.001). As with other HCV monotherapies, antibody-treated subjects had resistance-associated variants at the time of viral rebound. A combination study of MBL-HCV1 with a direct-acting antiviral is underway.

Для цитирования: Chung R T, Gordon F D, Curry M P, Schiano T D, Emre S, Corey K, Markmann J F, Hertl M, Pomposelli J J, Pomfret E A, Florman S, Schilsky M, Broering T J, Finberg R W, Szabo G, Zamore P D, Khettry U, Babcock G J, Ambrosino D M, Leav B, Leney M, Smith H L, Molrine D C. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study.. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2013. DOI: 10.1111/ajt.12083.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.